Needham reiterated coverage on PhaseBio Pharmaceuticals with a new price target

6/17/21 11:20:30 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Needham reiterated coverage of PhaseBio Pharmaceuticals with a rating of Buy and set a new price target of $15.00 from $16.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PHAS

Date	Price Target	Rating	Analyst
9/28/2022	$15.00 → $1.00	Buy → Hold	Stifel
10/13/2021	$15.00	Buy	Stifel